Chief Medical Officer, Amgen
| Role | Organisation | Sources |
|---|---|---|
| Chief Medical Officer (former) | Amgen | GBS Ventures (17 Oct 2011), GBS Ventures (31 May 2007) |
Stories naming Dr George Morstyn. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
GBS Ventures announces it has fully wound down its 1998 biotech fund with returns in the top quartile of US peers, recalling portfolio listings, Dynamic Hearing's sale to Wolfson, and its $122.5m fourth fund.
A 2007 announcement that Australian biotech ChemGenex Pharmaceuticals appointed former Amgen executive Dr George Morstyn to its board, with CEO Greg Collier citing his oncology development and commercialisation expertise.